Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov;13(11):1652-1663.
doi: 10.1016/j.jiph.2020.09.008. Epub 2020 Sep 29.

Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis

Haytham Tlayjeh  1 , Olaa H Mhish  2 , Mushira A Enani  3 , Alya Alruwaili  4 , Rana Tleyjeh  2 , Lukman Thalib  5 , Leslie Hassett  6 , Yaseen M Arabi  1 , Tarek Kashour  7 , Imad M Tleyjeh  8
Affiliations
Meta-Analysis

Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis

Haytham Tlayjeh et al. J Infect Public Health. 2020 Nov.

Abstract

Background: To systematically review the literature about the association between systemic corticosteroid therapy (CST) and outcomes of COVID-19 patients.

Methods: We searched Medline, Embase, EBM Reviews, Scopus, Web of Science, and preprints up to July 20, 2020. We included observational studies and randomized controlled trials (RCT) that assessed COVID-19 patients treated with CST. We pooled adjusted effect estimates of mortality and other outcomes using a random effect model, among studies at low or moderate risk for bias. We assessed the certainty of evidence for each outcome using the GRADE approach.

Results: Out of 1067 citations screened for eligibility, one RCT and 19 cohort studies were included (16,977 hospitalized patients). Ten studies (1 RCT and 9 cohorts) with 10,278 patients examined the effect of CST on short term mortality. The pooled adjusted RR was 0.92 (95% CI 0.69-1.22, I2 = 81.94%). This effect was observed across all stages of disease severity. Four cohort studies examined the effect of CST on composite outcome of death, ICU admission and mechanical ventilation need. The pooled adjusted RR was 0.41(0.23-0.73, I2 = 78.69%). Six cohort studies examined the effect of CST on delayed viral clearance. The pooled adjusted RR was 1.47(95% CI 1.11-1.93, I2 = 43.38%).

Conclusion: In this systematic review, as of July 2020, heterogeneous and low certainty cumulative evidence based on observational studies and one RCT suggests that CST was not associated with reduction in short-term mortality but possibly with a delay in viral clearance in patients hospitalized with COVID-19 of different severities. However, the discordant results between the single RCT and observational studies as well as the heterogeneity observed across observational studies, call for caution in using observational data and suggests the need for more RCTs to identify the clinical and biochemical characteristics of patients' population that could benefit from CST.

Keywords: COVID-19; Corticosteroids; Efficacy; Meta-analysis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of included studies.
Fig. 2
Fig. 2
A: Association between corticosteroids use and short-term mortality in COVID-19 patients: (All cohorts and 1 RCT). B: ROBINS-I quality assessment of included studies.
Fig. 3
Fig. 3
A: Association between corticosteroids use and short-term mortality in COVID-19 patients: By disease severity subgroups. B: Association between corticosteroids use and delayed viral clearance in COVID-19 patients.
See this image and copyright information in PMC

References

    1. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. - PMC - PubMed
    1. Zhang W., Zhao Y., Zhang F., Wang Q., Li T., Liu Z. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214 - PMC - PubMed
    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. - PubMed
    1. Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120–128. - PMC - PubMed
    1. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. - PMC - PubMed

Substances